nach oben

International Journal of Mental Health and Addiction

02.02.2024 | Original Article

Prazosin Enhances the Effectiveness of Mirtazapine on Anxiety- and Depression-Like Behaviors in Rats during Cocaine Withdrawal

verfasst von: Susana Barbosa-Méndez, Alberto Salazar-Juárez

Erschienen in: International Journal of Mental Health and Addiction

Einloggen, um Zugang zu erhalten

Abstract

Anxiety and depression, key symptoms of the cocaine withdrawal syndrome in human addicts, are considered the main factors that precipitate relapse in chronic cocaine addiction. Pharmacological therapeutic strategies should 1) decrease the cocaine-reinforcing effects and 2) decrease the adverse symptoms of cocaine withdrawal. Therefore, it requires improving the effect of effective therapy (mirtazapine) through combination with other (s) effective therapies (prazosin). This study sought to determine whether chronic dosing of mirtazapine plus prazosin during cocaine withdrawal reduced depression- and anxiety-like behaviors that characterize cocaine withdrawal in Wistar rats. Cocaine-pre-treated Wistar rats were subjected to a 60-day cocaine withdrawal period during which depression- and anxiety-like behaviors were evaluated in open field tests (OFT), the elevated plus-maze (EPM), the light–dark box test (LDT), the forced swimming test (FST), and spontaneous locomotor activity (SLA). We found 1) that chronic dosing of mirtazapine (30 mg/kg) + prazosin (1 mg/kg) decreased depression- and anxiety-like behaviors induced by 10 mg/kg of cocaine during the 60-day cocaine withdrawal. 2) prazosin enhanced the effect of mirtazapine on depression- and anxiety-like behaviors and 3) oxymetazoline blocked the prazosin-induced effect. Our results suggest that the pharmacological effect of mirtazapine on its target sites of action (α₂-adrenergic and 5-HT₁, 5-HT_2A and 5-HT₃ receptors) and of prazosin (α₁-adrenergic) within the brain may improve depression- and anxiety-like behaviors for long periods. Therefore, the findings support the use of a combination of mirtazapine + prazosin as a potentially effective therapy to reduce anxiety and depressive-like behavior during cocaine withdrawal.

Nur mit Berechtigung zugänglich

Afshar, M., Knapp, C. M., Sarid-Segal, O., Devine, E., Colaneri, L. S., Tozier, L., Waters, M. E., Putnam, M. A., & Ciraulo, D. A. (2012). The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. American Journal of Drug and Alcohol Abuse, 38, 181–186.PubMedCrossRef

Anttila, S. A., & Leinonen, E. V. (2001). A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Reviews, 7, 249–264.PubMedPubMedCentralCrossRef

Araos, P., Vergara-Moragues, E., Pedraz, M., Pavón, F. J., Campos, C. R., Calado, M., Ruiz, J. J., García-Marchena, N., Gornemann, I., Torrens, M., & Rodríguez de Fonseca, F. (2014). Psychopathological comorbidity in cocaine users in outpatient treatment. Adicciones, 26, 15–26.PubMedCrossRef

Bahi, A. (2016). Sustained lentiviral-mediated overexpression of microRNA124a in the dentate gyrus exacerbates anxiety- and autism-like behaviors associated with neonatal isolation in rats. Behavioural Brain Research, 311, 298–308.PubMedCrossRef

Bahi, A., Al Mansouri, S., Al Memari, E., Al Ameri, M., Nurulain, S. M., & Ojha, S. (2014a). β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiology & Behavior, 135, 119–124.CrossRef

Bahi, A., Schwed, J. S., Walter, M., Stark, H., & Sadek, B. (2014b). Anxiolytic and antidepressant-like activities of the novel and potent non-imidazole histamine H³ receptor antagonist ST-1283. Drug. Des. Devel. Ther., 8, 627–637.PubMedPubMedCentral

Barbosa-Méndez, S., & Salazar-Juárez, A. (2019). Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal. Journal of Psychopharmacology, 33, 589–605.PubMedCrossRef

Barbosa-Méndez, S., Leff, P., Arías-Caballero, A., Hernández-Miramontes, R., Heinze, G., & Salazar-Juárez, A. (2017a). Mirtazapine attenuates cocaine seeking in rats. Journal of Psychiatric Research, 92, 38–46.PubMedCrossRef

Barbosa-Méndez, S., Matus-Ortega, M., & Salazar-Juárez, A. (2017b). Synergistic interactions between mirtazapine and prazosin prevent the induction and expression of behavioral sensitization to cocaine in rats. Physiology & Behavior, 180, 137–145.CrossRef

Barbosa-Méndez, S., Matus-Ortega, M., Jacinto-Gutiérrez, S., & Salazar-Juárez, A. (2018). Mirtazapine impairs acquisition and reinstatement of cocaine-induced place preference in rats. European Journal of Pharmacology, 820, 183–190.PubMedCrossRef

Bentley, G. A., Newton, S. H., & Starr, J. (1983). Studies on the antinociceptive action of alpha agonist drugs and their interactions with opioid mechanisms. British Journal of Pharmacology, 79, 125–134.PubMedPubMedCentralCrossRef

Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009). Pharmacologic alternatives to antidepressants in posttraumatic stress disorder, a systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 169–180.PubMedCrossRef

Bijak, M. (1989). Antidepressant drugs potentiate the alpha 1-adrenoceptor effect in hippocampal slices. European Journal of Pharmacology, 166, 183–191.PubMedCrossRef

Bittolo, T., Raminelli, C. A., Deiana, C., Baj, G., Vaghi, V., Ferrazzo, S., Bernareggi, A., & Tongiorgi, E. (2016). Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice. Science and Reports, 6, 19796.CrossRefADS

Byers, M. G., Allison, K. M., Wendel, C. S., & Lee, J. K. (2010). Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans, an assessment of long-term comparative effectiveness and safety. Journal of Clinical Psychopharmacology, 30, 225–229.PubMedCrossRef

Chandrasekaran, P. K. (2008). Employing mirtazapine to aid benzodiazepine withdrawal. Singapore Medical Journal, 49, e166–e167.PubMed

Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., Tansella, M., & Barbui, C. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants, a multiple-treatments meta-analysis. Lancet, 373, 746–758.PubMedCrossRef

Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006). Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders, results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67, 247–257.PubMedCrossRef

Cornelius, J. R., Douaihy, A. B., Clark, D. B., Chung, T., Wood, D. S., & Daley, D. (2012). Mirtazapine in Comorbid Major Depression and Alcohol Dependence. An Open-Label Trial. J. Dual Diagn., 8, 200–204.PubMed

Cornelius, J. R., Douaihy, A. B., Clark, D. B., Daley, D. C., Chung, T. A., Wesesky, M. A., Wood, D. S., & Salloum, I. (2013). Mirtazapine in Comorbid Major Depression and Alcohol Use Disorder, A Long-Term Follow-Up Study. Journal of Addictive Behaviors, Therapy & Rehabilitation, 3, 1560.

Cornelius, J. R., Chung, T., Douaihy, A. B., Kirisci, L., Glance, J., Kmiec, J., FitzGerald, D., Wesesky, M. A., & Salloum, I. (2016). Mirtazapine in comorbid major depression and an alcohol use disorder, A double-blind placebo-controlled pilot trial. Psychiatry Research, 242, 326–330.PubMedPubMedCentralCrossRef

Crawley, J., & Goodwin, F. K. (1980). Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacology, Biochemistry and Behavior, 13, 167–170.PubMedCrossRef

Croom, K. F., Perry, C. M., & Plosker, G. L. (2009). Mirtazapine, A review of its use in major depression and other psychiatric disorders. CNS Drugs, 23, 427–452.PubMedCrossRef

Cryan, J. F., Page, M. E., & Lucki, I. (2005). Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology Berl., 182, 335–344.PubMedCrossRef

de Oliveira, C., Mdo, C., da Silva, F. C., Silva, M. I., Moura, B. A., Macêdo, D. S., Woods, D. J., Fonteles, M. M., de Vasconcelos, S. M., & de Sousa, F. C. (2012). Reversal of cocaine withdrawal-induced anxiety by ondansetron, buspirone, and propranolol. Behavioural Brain Research, 231, 116–123.CrossRef

Doze, V. A., Handel, E. M., Jensen, K. A., Darsie, B., Luger, E. J., Haselton, J. R., Talbot, J. N., & Rorabaugh, B. R. (2009). alpha (1A.- and alpha (1B.-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Research, 1285, 148–157.PubMedPubMedCentralCrossRef

Drapier, D., Bentué-Ferrer, D., Laviolle, B., Millet, B., Allain, H., Bourin, M., & Reymann, J. M. (2007). Effects of acute fluoxetine, paroxetine, and desipramine on rats tested on the elevated plus-maze. Behavioural Brain Research, 176, 202–209.PubMedCrossRef

D’Souza, M. S., & Markou, A. (2010). Neural substrates of psychostimulant withdrawal-induced anhedonia. Current Topics in Behavioral Neurosciences, 3, 119–178.PubMedCrossRef

El Hage, C., Rappeneau, V., Etievant, A., Morel, A. L., Scarna, H., Zimmer, L., & Bérod, A. (2012). Enhanced anxiety observed in cocaine withdrawn rats is associated with altered reactivity of the dorsomedial prefrontal cortex. PLoS ONE, 7, e43535.PubMedPubMedCentralCrossRefADS

Erb, S., Kayyali, H., & Romero, K. (2006). A study of the lasting effects of cocaine pre-exposure on anxiety-like behaviors under baseline conditions and in response to central injections of corticotropin-releasing factor. Pharmacology, Biochemistry and Behavior, 85, 206–213.PubMedCrossRef

Fox, H. C., Anderson, G. M., Tuit, K., Hansen, J., Kimmerling, A., Siedlarz, K. M., Morgan, P. T., & Sinha, R. (2012). Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals, preliminary findings. Alcoholism, Clinical and Experimental Research, 36, 351–360.PubMedCrossRef

Gambi, F., De Berardis, D., Campanella, D., Carano, A., Sepede, G., Salini, G., Mezzano, D., Cicconetti, A., Penna, L., Salerno, R. M., & Ferro, F. M. (2005). Mirtazapine treatment of generalized anxiety disorder, a fixed dose, open label study. Journal of Psychopharmacology, 19, 483–487.PubMedCrossRef

Gawin, F. H., & Kleber, H. D. (1986). Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical Observations. Arch Gen Psychiatry, 43, 107–113.PubMedCrossRef

Goodnick, P. J., Puig, A., DeVane, C. L., & Freund, B. V. (1999). Mirtazapine in major depression with comorbid generalized anxiety disorder. Journal of Clinical Psychiatry, 60, 446–448.PubMedCrossRef

Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders, results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry, 61, 807–816.PubMedCrossRef

Grasmäder, K., Verwohlt, P. L., Kühn, K. U., Frahnert, C., Hiemke, C., Dragicevic, A., von Widdern, O., Zobel, A., Maier, W., & Rao, M. L. (2005). Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry, 38, 113–117.PubMedCrossRef

Green, B. (2014). Prazosin in the treatment of PTSD. Journal of Psychiatric Practice, 20, 253–259.PubMedCrossRef

Gross-Isseroff, R., Dillon, K. A., Fieldust, S. J., & Biegon, A. (1990). Autoradiographic analysis of alpha 1-noradrenergic receptors in the human brain postmortem. Effect of Suicide. Arch Gen Psychiatry., 47, 1049–1053.PubMedCrossRef

Guo, P., Fang, Y., Feng, M., Zhao, X., Wang, S., Qian, M., Huang, J., & Chen, H. (2022). Case report, Prazosin augmentation for treating comorbid treatment-resistant depression and chronic post-traumatic stress disorder. Front. Psychiatry., 13, 803220.PubMedPubMedCentralCrossRef

Haddjeri, N., Blier, P., & de Montigny, C. (1997). Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn-Schmiedeberg’s Archives of Pharmacology, 355, 20–29.PubMedCrossRef

Hanft, G., & Gross, G. (1990). The effect of reserpine, desipramine and thyroid hormone on alpha 1a- and alpha 1b-adrenoceptor binding sites, evidence for a subtype-specific regulation. British Journal of Clinical Pharmacology, 30(Suppl 1), 125S-127S.PubMedPubMedCentral

Hanft, G. G., Gross, J. J., Beckeringh, C., & Korstanje, C. (1989). Alpha 1-adrenoceptors, the ability of various agonists and antagonists to discriminate between two distinct [H]prazosin binding sites. Journal of Pharmacy and Pharmacology, 41, 714–716.PubMedCrossRef

Hashimoto, T., Shiina, A., & Hasegawa, T. (2016). Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder, a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial. Annals of General Psychiatry, 19(15), 27.CrossRef

Jensen, K. L., Jensen, S. B., & Madsen, K. L. (2022). A Mechanistic overview of approaches for the treatment of psychostimulant dependence Frontiers in Pharmacology, 13, 854176.PubMedPubMedCentralCrossRef

Jiménez-Rivera, C. A., Feliu-Mojer, M., & Vázquez-Torres, R. (2006). Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization, Ann. N.Y. Academy of Sciences, 1074, 390–402.ADS

Kaminska, K., & Rogoz, Z. (2016). The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats. Journal of Physiology and Pharmacology, 67, 471–480.PubMed

Kampman, K. M., Alterman, A. I., Volpicelli, J. R., Maany, I., Muller, E. S., Luce, D. D., Mulholland, E. M., Jawad, A. F., Parikh, G. A., Mulvaney, F. D., Weinrieb, R. M., & O’Brien, C. P. (2001a). Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychology of Addictive Behaviors, 15, 52–59.PubMedCrossRef

Kampman, K. M., Volpicelli, J. R., Mulvaney, F., Alterman, A. I., Cornish, J., Gariti, P., Cnaan, A., Poole, S., Muller, E., Acosta, T., Luce, D., & O’Brien, C. (2001b). Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug and Alcohol Dependence, 63, 69–78.PubMedCrossRef

Kampman, K. M., Volpicelli, J. R., Mulvaney, F., Rukstalis, M., Alterman, A. I., & Pettinati, H. (2002). Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. Addictive Behaviors, 27, 251–260.PubMedCrossRef

Kampman, K. M., Dackis, C., Lynch, K. G., Pettinati, H., Tirado, C., Gariti, P., Sparkman, T., Atzram, M., & O’Brien, C. P. (2006). A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug and Alcohol Dependence, 85, 129–137.PubMedCrossRef

Kaye, J. T., Fronk, G. E., Zgierska, A. E., Cruz, M. R., Rabago, D., & Curtin, J. J. (2019). Acute prazosin administration does not reduce stressor reactivity in healthy adults. Psychopharmacology Berl., 236, 3371–3382.PubMedPubMedCentralCrossRef

Klimek, V., Zak-Knapik, J., & Maj, J. (1991). Antidepressants given repeatedly increase the alpha 1-adrenoceptor agonist affinity in the rat brain. Polish Journal of Pharmacology and Pharmacy, 43, 347–352.PubMed

Koob, G. F., & Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 24, 97–129.PubMedCrossRef

Koob, G. F., & Volkow, N. D. (2016). Neurobiology of Addiction, a Neurocircuitry Analysis. Lancet Psychiatry, 3, 760–773.PubMedPubMedCentralCrossRef

Kreiner, G., Bielawski, A., Zelek-Molik, A., Kowalska, M., & Nalepa, I. (2004). Chronic treatment with citalopram does not affect the expression of alpha1-adrenergic receptor (alpha1-AR. subtypes. Polish Journal of Pharmacology, 56, 831–836.PubMed

Ladrón de Guevara-Miranda, D., Millón, C., Rosell-Valle, C., Pérez-Fernández, M., Missiroli, M., Serrano, A., Pavón, F. J., Rodríguez de Fonseca, F., Martínez-Losa, M., Álvarez-Dolado, M., Santín, L. J., & Castilla-Ortega, E. (2017). Long-lasting memory deficits in mice withdrawn from cocaine are concomitant with neuroadaptations in hippocampal basal activity, GABAergic interneurons and adult neurogenesis. Disease Models & Mechanisms, 10, 323–336.

Lai, H. M., Clearym, M., Sitharthan, T., & Hunt, G. E. (2015). Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014, A systematic review and meta-analysis. Drug and Alcohol Dependence, 154, 1–13.PubMedCrossRef

Langer, S. Z., & Dubocovich, M. L. (1981). Cocaine and amphetamine antagonize the decrease of noradrenergic neurotransmission elicited by oxymetazoline but potentiate the inhibition by alpha-methylnorepinephrine in the perfused cat spleen. Journal of Pharmacology and Experimental Therapeutics, 216, 162–171.PubMed

Lapmanee, S., Charoenphandhu, N., Krishnamra, N., & Charoenphandhu, J. (2012). Anxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats. Behavioural Brain Research, 231, 20–28.PubMedCrossRef

Lapmanee, S., Charoenphandhu, J., & Charoenphandhu, N. (2013). Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors. Behavioural Brain Research, 250, 316–325.PubMedCrossRef

Liappas, J., Paparrigopoulos, T., Tzavellas, E., & Christodoulou, G. (2003). Alcohol detoxification and social anxiety symptoms, a preliminary study of the impact of mirtazapine administration. Journal of Affective Disorders, 76, 279–284.PubMedCrossRef

Liappas, J., Paparrigopoulos, T., Malitas, P., Tzavellas, E., & Christodoulou, G. (2004). Mirtazapine improves alcohol detoxification. Journal of Psychopharmacology, 18, 88–93.PubMedCrossRef

Maj, J., Klimek, V., & Nowak, G. (1985). Antidepressant drugs given repeatedly increase binding to alpha 1-adrenoceptors in the rat cortex. European Journal of Pharmacology, 119, 113–116.PubMedCrossRef

Masand, P. S., & Gupta, S. (2002). Long-term side effects of newer-generation antidepressants, SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Annals of Clinical Psychiatry, 14, 175–182.PubMedCrossRef

McCall, W. V., Pillai, A., Case, D., McCloud, L., Nolla, T., Branch, F., Youssef, N. A., Moraczewski, J., Tauhidul, L., Pandya, C. D., & Rosenquist, P. B. (2018). A Pilot, Randomized Clinical Trial of Bedtime Doses of Prazosin Versus Placebo in Suicidal Posttraumatic Stress Disorder Patients With Nightmares. Journal of Clinical Psychopharmacology, 38, 618–621.PubMedCrossRef

McPherson, G. A., & Summers, R. J. (1982). A study of alpha 1-adrenoceptors in rat renal cortex, comparison of [3H]-prazosin binding with the alpha 1-adrenoceptor modulating gluconeogenesis under physiological conditions. British Journal of Pharmacology, 77, 177–184.PubMedPubMedCentralCrossRef

Menkes, D. B. (1991). Alpha 1-noradrenergic receptor binding in suicide victims. Archives of General Psychiatry, 48, 859–860.PubMedCrossRef

Menkes, D. B., Aghajanian, G. K., & Gallager, D. W. (1983a). Chronic antidepressant treatment enhances agonist affinity of brain alpha 1-adrenoceptors. European Journal of Pharmacology, 87, 35–41.PubMedCrossRef

Menkes, D. B., Kehne, J. H., Gallager, D. W., Aghajanian, G. K., & Davis, M. (1983b). Functional supersensitivity of CNS alpha 1-adrenoceptors following chronic antidepressant treatment. Life Sciences, 33, 181–188.PubMedCrossRef

Michel, A. D., Loury, D. N., & Whiting, R. L. (1989). Identification of a single alpha 1-adrenoceptor corresponding to the alpha 1A-subtype in rat submaxillary gland. British Journal of Pharmacology, 98, 883–889.PubMedPubMedCentralCrossRef

Milivojevic, V., Angarita, G. A., Hermes, G., Sinha, R., & Fox, H. C. (2020). Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder. Alcoholism, Clinical and Experimental Research, 44, 1488–1496.PubMedPubMedCentralCrossRef

Muguruza, C., Miranda-Azpiazu, P., Díez-Alarcia, R., Morentin, B., González-Maeso, J., Callado, L. F., & Meana, J. J. (2014). Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder, effect of antidepressant treatment. Neuropharmacology, 86, 311–318.PubMedCrossRef

Mulvaney, F. D., Alterman, A. I., Boardman, C. R., & Kampman, K. (1999). Cocaine abstinence symptomatology and treatment attrition. Journal of Substance Abuse Treatment, 16, 129–135.PubMedCrossRef

Nanni-Alvarado, R., Marín-Navarrete, R., Gonzalez, M., Lima, C., Barbosa-Méndez, S., & Salazar-Juárez, A. (2022). Effect of mirtazapine on craving in cocaine depended patients. International Journal Mental Health & Addiction, 20, 2770–2786.CrossRef

Nowak, G. (1987). A two-week treatment with antidepressants does not increase the density of 3H-prazosin binding sites in the cerebral cortex of elderly rats. Polish Journal of Pharmacology and Pharmacy, 39, 721–724.PubMed

Nowakowska, E., Chodera, A., & Kus, K. (1996). Anxiolytic and memory improving activity of fluoxetine. Polish Journal of Pharmacology, 48, 255–260.PubMed

Pedraz, M., Martín-Velasco, A. I., García-Marchena, N., Araos, P., Serrano, A., Romero-Sanchiz, P., Suárez, J., Castilla-Ortega, E., Barrios, V., Campos-Cloute, R., Ruiz, J. J., Torrens, M., Chowen, J. A., Argente, J., de la Torre, R., Santín, L. J., Villanúa, M. Á., Rodríguez de Fonseca, F., & Pavón, F. J. (2015). Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders, relationship to psychiatric comorbidity. PLoS ONE., 10(e011861010), 1371.

Pedraz, M., Araos, P., García-Marchena, N., Serrano, A., Romero-Sanchiz, P., Suárez, J., Castilla-Ortega, E., Mayoral-Cleries, F., Ruiz, J.J., Pastor, A., Barrios, V., Chowen, J.A., Argente, J., Torrens, M., de la Torre, R., Rodríguez-De Fonseca, F., Pavón, F.J. (2015) Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings. Frontiers in Psychiatry 6. https://doi.org/10.3389/fpsyt.2015.00017

Pellow, S., & File, S. E. (1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze, a novel test of anxiety in the rat. Pharmacology, Biochemistry and Behavior, 24, 525–529.PubMedCrossRef

Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985). Validation of open, closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods, 14, 149–167.PubMedCrossRef

Porsolt, R. D., Bertin, A., & Jalfre, M. (1977a). Behavioral despair in mice, a primary screening test for antidepressants. Archives Internationales De Pharmacodynamie Et De Therapie, 229, 327–336.PubMed

Porsolt, R. D., Le Pichon, M., & Jalfre, M. (1977b). Depression, a new animal model sensitive to antidepressant treatments. Nature, 266, 730–732.PubMedCrossRefADS

Porsolt, R. D., Bertin, A., & Jalfre, M. (1978). Behavioural despair in rats and mice, strain differences and the effects of imipramine. European Journal of Pharmacology, 51, 291–294.PubMedCrossRef

Porsolt, R.D., Brossard, G., Hautbois, C., Roux, S. (2001) Rodent models of depression, forced swimming and tail suspension behavioral despair tests in rats and mice. Current Protocol Neuroscience Chapter 8, Unit 8.10A. https://doi.org/10.1002/0471141755.ph0508s10

Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., Romesser, J., Rosenheck, R., Shih, M. C., Stein, M. B., Swift, R., Gleason, T., Lu, Y., & Huang, G. D. (2018). Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. New England Journal of Medicine, 378, 507–517.PubMedCrossRef

Rasmussen, D. D., Kincaid, C. L., & Froehlich, J. C. (2017). Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations. Alcohol and Alcoholism, 52, 5–11.PubMedCrossRef

Rénéric, J. P., Bouvard, M., & Stinus, L. (2002). In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed. European Neuropsychopharmacology, 12, 159–171.PubMedCrossRef

Robert, G., Drapier, D., Bentué-Ferrer, D., Renault, A., & Reymann, J. M. (2011). Acute and chronic anxiogenic-like response to fluoxetine in rats in the elevated plus-maze, modulation by stressful handling. Behavioural Brain Research, 220, 344–348.PubMedCrossRef

Rogóz, Z., Skuza, G., Dlaboga, D., Maj, J., & Dziedzicka-Wasylewska, M. (2001). Effect of repeated treatment with tianeptine and fluoxetine on the central alpha (1-adrenergic system. Neuropharmacology, 41, 360–368.PubMedCrossRef

Rogóz, Z., Margas, W., Skuza, G., Solich, J., Kuśmider, M., & Dziedzicka-Wasylewska, M. (2002b). Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors. Polish Journal of Pharmacology, 54, 593–603.PubMed

Rogoz, Z. (2010). Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice. Pharmacological Reports, 62, 1191–1196.PubMedCrossRef

Rogoz, Z. (2012). Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. Pharmacological Reports, 64, 1567–1572.PubMedCrossRef

Rogoz, Z., Wrobel, A., Dlaboga, D., Maj, J., & Dziedzicka-Wasylewska, M. (2002a). Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. Journal of Physiology and Pharmacology, 53, 105–116.PubMed

Rogóż, Z., & Kabziński, M. (2011). Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacological Reports, 63, 1533–1538.PubMedCrossRef

Rogóż, Z., & Skuza, G. (2011). Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. Pharmacological Reports, 63, 1547–1552.PubMedCrossRef

Rogóż, Z., Kabziński, M., Sadaj, W., Rachwalska, P., & Gądek-Michalska, A. (2012). Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacological Reports, 64, 1391–1399.PubMedCrossRef

Salazar-Juárez, A., Barbosa-Méndez, S., Jurado, N., Hernández-Miramontes, R., Leff, P., & Antón, B. (2016). Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats. Prog. Neuropsychopharmacol. Biological Psychiatry, 68, 15–24.

Salazar-Juárez, A., Barbosa-Méndez, S., Merino-Reyes, P., Matus-Ortega, M., Hernández-Calderón, J. A., & Antón, B. (2017). Chronic dosing with mirtazapine does not produce sedation in rats. Revista Brasileira De Psiquiatria, 39, 228–236.PubMedPubMedCentralCrossRef

Sarnyai, Z., Bíró, E., Gardi, J., Vecsernyés, M., Julesz, J., & Telegdy, G. (1995). Brain corticotropin-releasing factor mediates “anxiety-like” behavior induced by cocaine withdrawal in rats. Brain Research, 675, 89–97.PubMedCrossRef

Schutters, S. I., Van Megen, H. J., Van Veen, J. F., Denys, D. A., & Westenberg, H. G. (2010). Mirtazapine in generalized social anxiety disorder, a randomized, double-blind, placebo-controlled study. International Clinical Psychopharmacology, 25, 302–304.PubMedCrossRef

Silva, M. T., Alves, C. R., & Santarem, E. M. (1999). Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze. Brazilian Journal of Medical and Biological Research, 32, 333–339.PubMedCrossRef

Sinha, R., Wemm, S., Fogelman, N., Milivojevic, V., Morgan, P. M., Angarita, G. A., Hermes, G., & Fox, H. C. (2021). Moderation of Prazosin’s Efficacy by Alcohol Withdrawal Symptoms. American Journal of Psychiatry, 178, 447–458.PubMedCrossRef

Skelly, M. J., & Weiner, J. L. (2014). Chronic treatment with prazosin or duloxetine lessens concurrent anxiety-like behavior and alcohol intake, evidence of disrupted noradrenergic signaling in anxiety-related alcohol use. Brain and Behavior: A Cognitive Neuroscience Perspective, 4, 468–483.CrossRef

Sofuoglu, M., Dudish-Poulsen, S., Brown, S. B., & Hatsukami, D. K. (2003). Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug and Alcohol Dependence, 69, 273–282.PubMedCrossRef

Sofuoglu, M., Dudish-Poulsen, S., Poling, J., Mooney, M., & Hatsukami, D. K. (2005). The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users. Addictive Behaviors, 30, 1125–1134.PubMedCrossRef

Sofuoglu, M., Poling, J., Gonzalez, G., Gonsai, K., & Kosten, T. (2006). Cocaine withdrawal symptoms predict medication response in cocaine users. American Journal of Drug and Alcohol Abuse, 32, 617–627.PubMedCrossRef

Sugden, D., Anwar, N., & Klein, D. C. (1996). Rat pineal alpha 1-adrenoceptor subtypes, studies using radioligand binding and reverse transcription-polymerase chain reaction analysis. British Journal of Pharmacology, 118, 1246–1252.PubMedPubMedCentralCrossRef

Takamura, N., Masuda, T., Inoue, T., Nakagawa, S., & Koyama, T. (2012). The effects of the co-administration of the α₁-adrenoreceptor antagonist prazosin on the anxiolytic effect of citalopram in conditioned fear stress in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 39, 107–111.PubMedCrossRef

Taylor, H. R., Freeman, M. K., & Cates, M. E. (2008). Prazosin for treatment of nightmares related to posttraumatic stress disorder. American Journal of Health System Pharmacy, 65, 716–722.PubMedCrossRef

Tsutsumi, T., Sugawara, H., Ito, R., Asano, M., Shimizu, S., Ishigooka, J., & Nishimura, K. (2016). Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder. Neuropsychiatric Disease and Treatment, 12, 2533–2538.PubMedPubMedCentralCrossRef

Wada, T., Hasegawa, Y., & Ono, H. (1997). Characterization of alpha1-adrenoceptor subtypes in facilitation of rat spinal motoneuron activity. European Journal of Pharmacology, 340, 45–52.PubMedCrossRef

Watanabe, N., Omori, I. M., Nakagawa, A., Cipriani, A., Barbui, C., McGuire, H., Churchill, R., & Furukawa, T. A. (2008). Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression, systematic review and meta-analysis. Journal of Clinical Psychiatry, 69, 1404–1415.PubMedCrossRef

Watanabe, N., Omori, I. M., Nakagawa, A., Cipriani, A., Barbui, C., McGuire, H., Churchill, R., & Furukawa, T. A. (2010). MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: Systematic review and meta-analysis. CNS Drugs, 24, 35–53.PubMedCrossRef

Zhang, X. Y., & Kosten, T. A. (2005). Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biological Psychiatry, 57, 1202–1204.PubMedCrossRef

Zhang, X. Y., & Kosten, T. A. (2007). Previous exposure to cocaine enhances cocaine self-administration in an alpha 1-adrenergic receptor dependent manner. Neuropsychopharmacology, 32, 638–645.PubMedCrossRef

Titel: Prazosin Enhances the Effectiveness of Mirtazapine on Anxiety- and Depression-Like Behaviors in Rats during Cocaine Withdrawal
verfasst von: Susana Barbosa-Méndez
Alberto Salazar-Juárez
Publikationsdatum: 02.02.2024
Verlag: Springer US
Erschienen in: International Journal of Mental Health and Addiction
Print ISSN: 1557-1874
Elektronische ISSN: 1557-1882
DOI: https://doi.org/10.1007/s11469-024-01247-7

Neu im Fachgebiet Psychiatrie

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen